Ai-enabled drug discovery support

Immundnz is a UK-based contract research organization (CRO) specializing in experimental in vitro immunology research for drug discovery and development. The company provides customized solutions, including the design and application of tailored immune assays and translational human models to study immune interactions, risk assessment, and therapeutic efficacy. Its technical capabilities encompass a range of bioanalytical, protein-based, and cell-based techniques such as flow cytometry, mass spectrometry, microscopy, and various cell culture systems, including 2D, 3D, and microfluidics. Founded in 2016, the firm leverages deep expertise in immunology, biochemistry, and biomarker analysis to support research across therapeutic areas like oncology, immuno-oncology, neuro-immunology, and autoimmune diseases.

By providing these specialized services, Immundnz helps biopharmaceutical and biotechnology clients make informed decisions during non-clinical and pre-clinical stages of drug development. The company’s approach is centered on overcoming the complexity of modulating immune responses by offering bespoke assays that go beyond standardized testing. This service-oriented model is intended to assist partners in better understanding drug compound mechanisms of action, therapeutic safety, and efficacy, ultimately aiming to accelerate the drug discovery process through high-quality, translational data. The organization maintains an active profile with facilities located in Kent and at Alderley Park.